Shots:

• The companies collaborated for marketing and distribution of four biosimilars in Australia and New Zealand
• Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands- covering therapeutic categories across immunology- osteoporosis- oncology as well as ophthalmology
• Alvotech will manufacture and develop the products and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. Earlier- in Jun 2019- Cipla collaborated with Alvotech for the commercialization of AVT02- an adalimumab biosimilar- in select emerging markets

  Ref: Businesswire | Image: Cipla